ArticleEuropean journal of medical research2025
FBXO42 promotes hepatocellular carcinoma progression via mediating p57Kip2 ubiquitination and degradation.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), one of the most common malignancies, accounts for about 80% of all primary liver cancers. FBXO42 belongs to the F-box protein family and functions as a key component of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex, which is involved in the process of protein ubiquitination. The studies on the role of FBXO42 in different diseases are inadequate, especially in HCC.
methodsThe expression and the clinical features of FBXO42 in HCC were assessed using the HCCDB, TCGA, and ICGC databases. cBioPortal and SangerBox databases were used to analyze the genetic alterations and mutation profile of FBXO42. TIMER, TISIDB and GEPIA databases were used to examine the correlation of FBXO42 with tumor-infiltrating immune cells, tumor-associated fibroblasts and cancer stemness. CCK8 assay, clone formation assay and EDU assay were utilized to reveal the cell viability and proliferation ability. Meanwhile, transwell assay was used to assess the cellular migration. UbiBrowser and Co-IP revealed the FBXO42-interacting protein in HCC. The hTFtarget, ENCODE and CHEA databases were used to predict potential transcriptional regulators.
resultsOur data displayed that FBXO42 was highly expressed in HCC tissues and was associated with poor prognosis. Moreover, FBXO42 expression was correlated with immune cell infiltration and immune-related molecules, suggesting that FBXO42 may lead to a complex immune microenvironment in HCC. Meanwhile, our data revealed that the level of FBXO42 was positively associated with CAFs infiltration and cancer stemness. In addition, FBXO42 facilitated the malignant behaviors of HCC. Mechanistically, FBXO42 interacted p57Kip2, sequentially promoting p57Kip2 ubiquitination and degradation, ultimately leading to HCC progression. Finally, YY1 had been demonstrated to upregulate the expression of FBXO42 via transcriptional regulation.
conclusionsThis study revealed that FBXO42 promotes the malignancy of HCC through FBXO42-mediated p57Kip2 ubiquitination and degradation. Our findings underscore the possibility of FBXO42 as a potential therapeutic target for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.